Gaurav Munj 2022-03-04T06:42:16+00:00 CREATING SHAREHOLDER VALUE Site - Investor Relations Nav Overview Press Releases Events and Presentations Financial Filings Stock Information Corporate Governance Contact Upcoming and Recent Events Corporate Presentation SEC Filings Stock Quote & Chart Historical Lookup Governance Documents Committees Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Latest Press Releases January 13, 2025 Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy January 12, 2025 Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs View All Press Releases View All Events January 13, 2025 43rd Annual J.P. Morgan Healthcare Conference September 23, 2024 at 8:30 AM EDT Biohaven Topline Pivotal Trial Results for Troriluzole in Spinocerebellar Ataxia Listen to webcast May 29, 2024 Biohaven R&D Day at Yale School of Management View All Events View All BIOHAVEN EVENTSCORPORATE PRESENTATION LETTER FROM THE CHAIRMAN & CEO VIDEOS play video INTERVIEW WITH CEO VLAD CORIC M.D. ON CNBC’S FAST MONEY x play video Interview with CEO Vlad Coric M.D. on CNBC’s Mad Money x play video Diseases related to glutamate dysregulation x
Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Latest Press Releases January 13, 2025 Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy January 12, 2025 Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs View All Press Releases View All Events January 13, 2025 43rd Annual J.P. Morgan Healthcare Conference September 23, 2024 at 8:30 AM EDT Biohaven Topline Pivotal Trial Results for Troriluzole in Spinocerebellar Ataxia Listen to webcast May 29, 2024 Biohaven R&D Day at Yale School of Management View All Events View All BIOHAVEN EVENTSCORPORATE PRESENTATION LETTER FROM THE CHAIRMAN & CEO VIDEOS play video INTERVIEW WITH CEO VLAD CORIC M.D. ON CNBC’S FAST MONEY x play video Interview with CEO Vlad Coric M.D. on CNBC’s Mad Money x play video Diseases related to glutamate dysregulation x
January 13, 2025 Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy
January 12, 2025 Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
September 23, 2024 at 8:30 AM EDT Biohaven Topline Pivotal Trial Results for Troriluzole in Spinocerebellar Ataxia Listen to webcast